Uniunea Europeană - română - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenți pentru dermatită, cu excepția corticosteroizilor - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sanofi winthrop industrie - franta - dupilumabum - sol. inj. in seringa preumpluta - 175mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sanofi-aventis deutschland gmbh - franta - dupilumabum - sol. inj. in stilou injector (pen) preumplut - 175mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sanofi winthrop industrie - franta - dupilumabum - sol. inj. in seringa preumpluta - 150mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sanofi winthrop industrie - franta - dupilumabum - sol. inj. in stilou injector (pen) preumplut - 150mg/ml - alte preparate de uz dermatologic alte preparate de uz dermatologic

Uniunea Europeană - română - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - artrita, reumatoida - imunosupresoare - kevzara în asociere cu metotrexat (mtx) este indicat pentru tratamentul moderat la sever activă artrita reumatoida (ra) la pacienţii adulţi care au răspuns inadecvat la, sau care sunt intoleranta la unul sau mai multe boli modificarea anti-reumatice droguri (dmard). kevzara poate fi administrat ca monoterapie în caz de intoleranţă la mtx sau atunci când tratamentul cu mtx este inadecvat.

Uniunea Europeană - română - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinom, pulmonar non-celulă mică - agenți antineoplazici - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - durvalumabum - conc. pt. sol. perf. - 50mg/ml - anticorpi monoclonali si conjugati anticorp medicament

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

astrazeneca ab - durvalumabum - concentrat pentru soluţie perfuzabilă - 120 mg/2,4 ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

astrazeneca ab - durvalumabum - concentrat pentru soluţie perfuzabilă - 500 mg/10 ml